Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study

Background: Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity. Methods: This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis. Results: Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity. Conclusions: Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-18
DOI
https://doi.org/10.3390/diagnostics16223845
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study

Martin Olivieri, Michael Weigand, Mathias Bruegel, Bernd H. Northoff et al.
3 links
Diagnostics
Hemophilia Treatment and Research
article

Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study

Martin Olivieri, Michael Weigand, Mathias Bruegel, Bernd H. Northoff, Daniel Teupser, Michael Spannagl, Jürgen Patzke, Lena Weindl
article en

Abstract

Background: Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity. Methods: This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis. Results: Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity. Conclusions: Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.

DiagnosticsVol. 16(22)
Philipps University of Marburg (DE), LMU Klinikum (DE), Institut für Laboratoriumsmedizin (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon